• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 16th May 2017

Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance

Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as a regional “pull” incentive. A new OHE Briefing has just been published entitled: Incentives…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as a regional “pull” incentive.

A new OHE Briefing has just been published entitled: Incentives for New Drugs to Tackle Anti-Microbial Resistance.

Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required.

Mechanisms designed to encourage companies to undertake R&D on new medicines are generally characterised as either “push” or “pull” programs. “Pull” mechanisms aim to create incentives by creating viable market demand and/or revenues when new products are approved. Pull incentives are key to stimulating R&D for new antibiotics and vaccines.

Push funding alone will not generate new medicines. Pull incentives are key to stimulating R&D for new antibiotics and vaccines. Our assessment is that both the Transferable Intellectual Property Rights and the Market Entry Reward should be further explored for use in Europe as a regional “pull” incentive. 

The new OHE Briefing looks at the proposals in the 2016 O’Neill Report, commissioned by the UK government, and the 2017 GUARD Report, commissioned by the German government.

Transferable Intellectual Property Rights and the Market Entry Reward both have strengths and weaknesses. The risk with Transferable Intellectual Property Rights is of overpaying relative to a Market Entry Reward. This can in part be overcome by using guard rails such as a variable period of patent extension.

The risk with the Market Entry Reward is of political risk and credibility. Is the funding source sustainable over a 15-20 year product development timeline, and is there a risk that the Reward can be changed at relatively short notice? Political risk will lead to a devaluation of the expected reward by companies, potentially requiring higher Market Entry Rewards to be offered than with Transferable Intellectual Property Rights.

Our assessment is that both Transferable Intellectual Property Rights and the Market Entry Reward should be further explored for use in the EU as a regional “pull” incentive. The current focus on the market entry reward should therefore be extended to include Transferable Intellectual Property Rights.

The O’Neill Report sets an objective of generating 15 new antibiotics per decade. The GUARD proposes one significant new antibiotic per year. A programme to incentivise 10-15 drugs per decade is therefore needed.

In simple terms 15 drugs over ten years at US$2 billion a drug (on our assumptions) re-quires a “pull” commitment of US$30 billion a decade, or US$3 billion per annum. This is much higher than the O’Neill Report recommendations of US$16 billion built around its assumptions of US$1 billion per product market entry rewards. The GUARD Report similarly refers to market entry rewards of US$1 billion per product.

The market entry rewards proposed by O’Neill and GUARD of US$1 billion per product are too low to stimulate discovery and development including pre-clinical research unless companies are also expected to make money from selling the product during its patent life. 

A lead group of countries need to work together to develop a set of pull incentives to drive new antibiotic and vaccine R&D in Europe and globally.

Access the full report here.

For more information please contact Adrian Towse at OHE.

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation
  • Briefing

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!